At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Computed tomography coronary angiography (CTCA) (radiation)
- How long the study runs
- Study runs about 96 months (dates as stated)
- About the drug or intervention
- Computed tomography coronary angiography (CTCA) — radiation: Single CTCA scan prior to kidney transplantation
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 16 Years and over
- Who
- All
- Number of participants
- 332
- Started
- 2024-01-24
- Last checked
- 2026-02
Plain English Summary
What is this study?
- • Testing a new treatment for cardiovascular diseases
- • Clinical study - 332 participants
- • Cardiovascular disease (for example, heart attack, stroke, heart failure) is the commonest complication of kidney failure
Who can take part?
- • Ages 16 Years and over
- • Diagnosed with cardiovascular diseases
Where?
- • Edinburgh - Royal Infirmary of Edinburgh
- • Glasgow - Queen Elizabeth Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Cardiovascular disease (for example, heart attack, stroke, heart failure) is the commonest complication of kidney failure. Kidney transplantation reduces cardiovascular risk but cardiovascular disease remains the commonest cause of death in patients following transplantation. Current strategies to assess patient's cardiovascular risk prior to kidney transplantation do not identify those at highest risk and do not improve outcomes. This study will use a heart scan known as computed tomography coronary angiography (CTCA) to see whether this scan can identify patients at highest risk of future cardiovascular disease prior to transplantation. Studies have shown it is able to do this in patients with normal kidney function. The aim of this study is to develop CTCA as an effective tool to risk stratify patients prior to kidney transplantation.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 16 Years and over
- Who can join: All genders
What the study is looking for
- ✓Has kidney failure and is on the waitlist for a kidney transplant
- ✓Age 16 years and over
- ✓Able to give agreement to take part
Who cannot take part
- ✗safety concern to CT scanning, including contrast allergy
- ✗Patients being considered for a simultaneous kidney-pancreas, kidney-liver and/or kidney-islet transplantation
- ✗Inability to give agreement to take part
See the full criteria
Where Is This Study? (2 UK sites)
Royal Infirmary of Edinburgh
Edinburgh EH16 4SA, United Kingdom
Queen Elizabeth Hospital
Glasgow G51 4TF, United Kingdom
How to Get in Touch
Gavin B Chapman, MBChB
Sponsor contactCONTACT
Neeraj Dhaun, MBChB
Sponsor contactCONTACT